BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 24763613)

  • 1. Combined PET/MRI improves diagnostic accuracy in patients with prostate cancer: a prospective diagnostic trial.
    Hartenbach M; Hartenbach S; Bechtloff W; Danz B; Kraft K; Klemenz B; Sparwasser C; Hacker M
    Clin Cancer Res; 2014 Jun; 20(12):3244-53. PubMed ID: 24763613
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is there an additional value of ¹¹C-choline PET-CT to T2-weighted MRI images in the localization of intraprostatic tumor nodules?
    Van den Bergh L; Koole M; Isebaert S; Joniau S; Deroose CM; Oyen R; Lerut E; Budiharto T; Mottaghy F; Bormans G; Van Poppel H; Haustermans K
    Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):1486-92. PubMed ID: 22284686
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 18F-Choline PET/MRI: The Additional Value of PET for MRI-Guided Transrectal Prostate Biopsies.
    Piert M; Montgomery J; Kunju LP; Siddiqui J; Rogers V; Rajendiran T; Johnson TD; Shao X; Davenport MS
    J Nucl Med; 2016 Jul; 57(7):1065-70. PubMed ID: 26985061
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prostate cancer: 1HMRS-DCEMR at 3T versus [(18)F]choline PET/CT in the detection of local prostate cancer recurrence in men with biochemical progression after radical retropubic prostatectomy (RRP).
    Panebianco V; Sciarra A; Lisi D; Galati F; Buonocore V; Catalano C; Gentile V; Laghi A; Passariello R
    Eur J Radiol; 2012 Apr; 81(4):700-8. PubMed ID: 21330082
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnostic value of integrated PET/MRI for detection and localization of prostate cancer: Comparative study of multiparametric MRI and PET/CT.
    Lee MS; Cho JY; Kim SY; Cheon GJ; Moon MH; Oh S; Lee J; Lee S; Woo S; Kim SH
    J Magn Reson Imaging; 2017 Feb; 45(2):597-609. PubMed ID: 27586519
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diffusion-weighted MRI, 11C-choline PET and 18F-fluorodeoxyglucose PET for predicting the Gleason score in prostate carcinoma.
    Chang JH; Lim Joon D; Lee ST; Hiew CY; Esler S; Gong SJ; Wada M; Clouston D; O'Sullivan R; Goh YP; Tochon-Danguy H; Chan JG; Bolton D; Scott AM; Khoo V; Davis ID
    Eur Radiol; 2014 Mar; 24(3):715-22. PubMed ID: 24192979
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [F(18)]-fluoroethylcholine combined in-line PET-CT scan for detection of lymph-node metastasis in high risk prostate cancer patients prior to radical prostatectomy: Preliminary results from a prospective histology-based study.
    Steuber T; Schlomm T; Heinzer H; Zacharias M; Ahyai S; Chun KF; Haese A; Klutmann S; Köllermann J; Sauter G; Mester J; Mikecz P; Fisch M; Huland H; Graefen M; Salomon G
    Eur J Cancer; 2010 Jan; 46(2):449-55. PubMed ID: 19969447
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostate cancer: combined FEC-PET/MRI improves diagnostic accuracy.
    Clyne M
    Nat Rev Urol; 2014 Jun; 11(6):306. PubMed ID: 24818855
    [No Abstract]   [Full Text] [Related]  

  • 9. 18F choline PET/CT in the preoperative staging of prostate cancer in patients with intermediate or high risk of extracapsular disease: a prospective study of 130 patients.
    Beheshti M; Imamovic L; Broinger G; Vali R; Waldenberger P; Stoiber F; Nader M; Gruy B; Janetschek G; Langsteger W
    Radiology; 2010 Mar; 254(3):925-33. PubMed ID: 20177103
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Index lesion characterization by (11)C-Choline PET/CT and Apparent Diffusion Coefficient parameters at 3 Tesla MRI in primary prostate carcinoma.
    Hernández-Argüello M; Quiceno H; Pascual I; Solorzano JL; Benito A; Collantes M; Rodríguez-Fraile M; Pardo J; Richter JA
    Prostate; 2016 Jan; 76(1):3-12. PubMed ID: 26390847
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Usefulness of MRI-assisted metabolic volumetric parameters provided by simultaneous (18)F-fluorocholine PET/MRI for primary prostate cancer characterization.
    Kim YI; Cheon GJ; Paeng JC; Cho JY; Kwak C; Kang KW; Chung JK; Kim EE; Lee DS
    Eur J Nucl Med Mol Imaging; 2015 Jul; 42(8):1247-56. PubMed ID: 25759164
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Simultaneous
    Eiber M; Weirich G; Holzapfel K; Souvatzoglou M; Haller B; Rauscher I; Beer AJ; Wester HJ; Gschwend J; Schwaiger M; Maurer T
    Eur Urol; 2016 Nov; 70(5):829-836. PubMed ID: 26795686
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of [(11)C]choline Positron Emission Tomography With T2- and Diffusion-Weighted Magnetic Resonance Imaging for Delineating Malignant Intraprostatic Lesions.
    Chang JH; Lim Joon D; Davis ID; Lee ST; Hiew CY; Esler S; Gong SJ; Wada M; Clouston D; O'Sullivan R; Goh YP; Bolton D; Scott AM; Khoo V
    Int J Radiat Oncol Biol Phys; 2015 Jun; 92(2):438-45. PubMed ID: 25864171
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Effect of Neoadjuvant Androgen Deprivation Therapy on Tumor Hypoxia in High-Grade Prostate Cancer: An
    Mainta IC; Zilli T; Tille JC; De Perrot T; Vallée JP; Buchegger F; Garibotto V; Miralbell R
    Int J Radiat Oncol Biol Phys; 2018 Nov; 102(4):1210-1218. PubMed ID: 29678527
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    Choi JY; Yang J; Noworolski SM; Behr S; Chang AJ; Simko JP; Nguyen HG; Carroll PR; Kurhanewicz J; Seo Y
    Radiology; 2017 Feb; 282(2):429-436. PubMed ID: 27513849
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ¹⁸F-DCFBC PET/CT for PSMA-Based Detection and Characterization of Primary Prostate Cancer.
    Rowe SP; Gage KL; Faraj SF; Macura KJ; Cornish TC; Gonzalez-Roibon N; Guner G; Munari E; Partin AW; Pavlovich CP; Han M; Carter HB; Bivalacqua TJ; Blackford A; Holt D; Dannals RF; Netto GJ; Lodge MA; Mease RC; Pomper MG; Cho SY
    J Nucl Med; 2015 Jul; 56(7):1003-1010. PubMed ID: 26069305
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Spine metastases in prostate cancer: comparison of technetium-99m-MDP whole-body bone scintigraphy, [(18) F]choline positron emission tomography(PET)/computed tomography (CT) and [(18) F]NaF PET/CT.
    Poulsen MH; Petersen H; Høilund-Carlsen PF; Jakobsen JS; Gerke O; Karstoft J; Steffansen SI; Walter S
    BJU Int; 2014 Dec; 114(6):818-23. PubMed ID: 24314065
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Value of bimodal (18)F-choline-PET/MRI and trimodal (18)F-choline-PET/MRI/TRUS for the assessment of prostate cancer recurrence after radiation therapy and radical prostatectomy.
    Paparo F; Piccardo A; Bacigalupo L; Romagnoli A; Piccazzo R; Monticone M; Cevasco L; Campodonico F; Conzi GM; Carmignani G; Rollandi GA
    Abdom Imaging; 2015 Aug; 40(6):1772-87. PubMed ID: 25579170
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prospective Comparison of 18F-Fluoromethylcholine Versus 68Ga-PSMA PET/CT in Prostate Cancer Patients Who Have Rising PSA After Curative Treatment and Are Being Considered for Targeted Therapy.
    Morigi JJ; Stricker PD; van Leeuwen PJ; Tang R; Ho B; Nguyen Q; Hruby G; Fogarty G; Jagavkar R; Kneebone A; Hickey A; Fanti S; Tarlinton L; Emmett L
    J Nucl Med; 2015 Aug; 56(8):1185-90. PubMed ID: 26112024
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Real-time MRI/US fusion-guided biopsy improves detection rates of prostate cancer in pre-biopsied patients].
    Maxeiner A; Fischer T; Stephan C; Cash H; Slowinski T; Kilic E; Durmus T
    Aktuelle Urol; 2014 May; 45(3):197-203. PubMed ID: 24902069
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.